Evidence map›Paper›PMID 38532275›Full record

ReviewCNS neuroscience & therapeutics2024

Malignancy-associated ischemic stroke: Implications for diagnostic and therapeutic workup.

Wanqing Xie, Szuyao Hsu, Yuxuan Lin, Lv Xie, Xia Jin, Ziyu Zhu, Yunlu Guo, Caiyang Chen, Dan Huang, Johannes Boltze and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in CNS neuroscience & therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wanqing XieDepartment of Anesthesiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0002-2849-9267
Szuyao HsuDepartment of Anesthesiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yuxuan LinDepartment of Anesthesiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Lv XieDepartment of Anesthesiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0003-2482-9975
Xia JinDepartment of Anesthesiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ziyu ZhuDepartment of Anesthesiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yunlu GuoDepartment of Anesthesiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0001-6073-5947
Caiyang ChenDepartment of Anesthesiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Dan HuangDepartment of Anesthesiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0001-7900-006X
Johannes BoltzeSchool of Life Sciences, University of Warwick, Coventry, UK.
Peiying LiDepartment of Anesthesiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0002-5721-9914

Funding

Innovative Research Team of High-level Local Universities in Shanghai SHSMU-ZLCX20211602Institutional Clinical Research Program PYII20-03National Natural Science Foundation of China 81971096National Natural Science Foundation of China 82061130224National Natural Science Foundation of China 91957111National Natural Science Foundation of China M-0671National Natural Science Foundation of China U22A20295New Frontier Technology Joint Research from Shanghai Shengkang Hospital Development Center SHDC12019102Newton Advanced Fellowship grant provided by the UK Academy of Medical Sciences NAF\R11\1010"Shanghai Outstanding Academic Leaders Program" from Shanghai Municipal Science and Technology Committee 20XD1422400"Shuguang Program" supported by Shanghai Education Development Foundation and Shanghai Municipal Education Commission 20SG17
6 · The paper itself

Abstract

backgroundPatients with malignancies have an increased risk of suffering ischemic stroke via several mechanisms such as coagulation dysfunction and other malignancy-related effects as well as iatrogenic causes. Moreover, stroke can be the first sign of an occult malignancy, termed as malignancy-associated ischemic stroke (MAS). Therefore, timely diagnostic assessment and targeted management of this complex clinical situation are critical.

findingsPatients with both stroke and malignancy have atypical ages, risk factors, and often exhibit malignancy-related symptoms and multiple lesions on neuroimaging. New biomarkers such as eicosapentaenoic acid and blood mRNA profiles may help in distinguishing MAS from other strokes. In terms of treatment, malignancy should not be considered a contraindication, given comparable rates of recanalization and complications between stroke patients with or without malignancies.

conclusionIn this review, we summarize the latest developments in diagnosing and managing MAS, especially stroke with occult malignancies, and provide new recommendations from recently emerged clinical evidence for diagnostic and therapeutic workup strategies.

Indexed as

Ischemic StrokeNeoplasmsStrokeHumansNeuroimagingRisk Factorsanticoagulationbiomarkerscancerischemic strokemalignancyreperfusion therapy

Identifiers

PMID38532275
PMCPMC10965754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.